Squarepoint’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-42,926
| Closed | -$1.03M | – | 4006 |
|
|
2021
Q1 | $1.03M | Sell |
42,926
-19,819
| -32% | -$368K | 0.01% | 1477 |
|
|
2020
Q4 | $916K | Buy |
62,745
+23,835
| +61% | +$316K | 0.01% | 1403 |
|
|
2020
Q3 | $553K | Sell |
38,910
-72,425
| -65% | -$1.11M | 0.01% | 1367 |
|
|
2020
Q2 | $1.64M | Sell |
111,335
-35,923
| -24% | -$365K | 0.03% | 706 |
|
|
2020
Q1 | $607K | Sell |
147,258
-89,155
| -38% | -$418K | 0.02% | 935 |
|
|
2019
Q4 | $1.14M | Sell |
236,413
-46,533
| -16% | -$257K | 0.01% | 1256 |
|
|
2019
Q3 | $1.72M | Buy |
282,946
+100,768
| +55% | +$629K | 0.02% | 922 |
|
|
2019
Q2 | $1.18M | Buy |
182,178
+134,084
| +279% | +$945K | 0.01% | 1162 |
|
|
2019
Q1 | $341K | Buy |
+48,094
| New | +$317K | ﹤0.01% | 1701 |
|
|
2018
Q2 | – | Sell |
-13,943
| Closed | -$76K | – | 2180 |
|
|
2018
Q1 | $76K | Buy |
13,943
+1,463
| +12% | +$7.27K | ﹤0.01% | 1593 |
|
|
2017
Q4 | $52K | Buy |
+12,480
| New | +$75.1K | ﹤0.01% | 2014 |
|
|
2017
Q1 | – | Sell |
-13,986
| Closed | -$171K | – | 2067 |
|
|
2016
Q4 | $171K | Buy |
+13,986
| New | +$166K | 0.01% | 1499 |
|
|
2016
Q2 | – | Sell |
-10,200
| Closed | -$54K | – | 1424 |
|
|
2016
Q1 | $54K | Buy |
+10,200
| New | +$56.8K | ﹤0.01% | 1092 |
|
Squarepoint's GNMK Position: Q2 2021 in Review
Squarepoint sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 42,926 shares — an estimated $1.03M sold.
Squarepoint first reported a position in GNMK in Q1 2016 and held it in 13 quarters. The position peaked at $1.72M in Q3 2019. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Squarepoint reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Squarepoint sold 42,926 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $1.03M.
- Squarepoint first reported a position in GenMark Diagnostics, Inc in Q1 2016 and held it in 13 quarters.
- Squarepoint's GenMark Diagnostics, Inc position peaked at $1.72M in Q3 2019.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.